These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27158463)

  • 21. The beta-cell in type 1 diabetes: What have we learned from proteomic studies?
    Crèvecoeur I; Rondas D; Mathieu C; Overbergh L
    Proteomics Clin Appl; 2015 Aug; 9(7-8):755-66. PubMed ID: 25641783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential of multimer technologies in type 1 diabetes prediction strategies.
    Fierabracci A
    Diabetes Metab Res Rev; 2011 Mar; 27(3):216-29. PubMed ID: 21309048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune intervention for type 1 diabetes mellitus.
    Skyler JS
    Int J Clin Pract Suppl; 2011 Feb; (170):61-70. PubMed ID: 21323814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thymic self-antigens for the design of a negative/tolerogenic self-vaccination against type 1 diabetes.
    Geenen V; Mottet M; Dardenne O; Kermani H; Martens H; Francois JM; Galleni M; Hober D; Rahmouni S; Moutschen M
    Curr Opin Pharmacol; 2010 Aug; 10(4):461-72. PubMed ID: 20434402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoimmune Diabetes: An Overview of Experimental Models and Novel Therapeutics.
    You S; Chatenoud L
    Methods Mol Biol; 2016; 1371():117-42. PubMed ID: 26530798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How apoptotic β-cells direct immune response to tolerance or to autoimmune diabetes: a review.
    Vives-Pi M; Rodríguez-Fernández S; Pujol-Autonell I
    Apoptosis; 2015 Mar; 20(3):263-72. PubMed ID: 25604067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type 1 diabetes vaccine candidates promote human Foxp3(+)Treg induction in humanized mice.
    Serr I; Fürst RW; Achenbach P; Scherm MG; Gökmen F; Haupt F; Sedlmeier EM; Knopff A; Shultz L; Willis RA; Ziegler AG; Daniel C
    Nat Commun; 2016 Mar; 7():10991. PubMed ID: 26975663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy for the prevention and treatment of type 1 diabetes.
    Goudy KS; Tisch R
    Int Rev Immunol; 2005; 24(5-6):307-26. PubMed ID: 16318984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The case for an autoimmune aetiology of type 1 diabetes.
    Mannering SI; Pathiraja V; Kay TW
    Clin Exp Immunol; 2016 Jan; 183(1):8-15. PubMed ID: 26313217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in the etiology and mechanisms of type 1 diabetes.
    Pugliese A
    Discov Med; 2014 Sep; 18(98):141-50. PubMed ID: 25227755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An insulin-like growth factor 2-derived self-antigen inducing a regulatory cytokine profile after presentation to peripheral blood mononuclear cells from DQ8+ type 1 diabetic adolescents: preliminary design of a thymus-based tolerogenic self-vaccination.
    Geenen V; Louis C; Martens H
    Ann N Y Acad Sci; 2004 Dec; 1037():59-64. PubMed ID: 15699493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects.
    Nakayama M; McDaniel K; Fitzgerald-Miller L; Kiekhaefer C; Snell-Bergeon JK; Davidson HW; Rewers M; Yu L; Gottlieb P; Kappler JW; Michels A
    Proc Natl Acad Sci U S A; 2015 Apr; 112(14):4429-34. PubMed ID: 25831495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B Quiet: Autoantigen-Specific Strategies to Silence Raucous B Lymphocytes and Halt Cross-Talk with T Cells in Type 1 Diabetes.
    Felton JL; Conway H; Bonami RH
    Biomedicines; 2021 Jan; 9(1):. PubMed ID: 33418839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-lymphocyte recognition of beta cells in type 1 diabetes: clinical perspectives.
    Boitard C
    Diabetes Metab; 2013 Dec; 39(6):459-66. PubMed ID: 24139825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes.
    Sarikonda G; Pettus J; Phatak S; Sachithanantham S; Miller JF; Wesley JD; Cadag E; Chae J; Ganesan L; Mallios R; Edelman S; Peters B; von Herrath M
    J Autoimmun; 2014 May; 50():77-82. PubMed ID: 24387802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of a cocktail regimen consisting of soluble galectin-1, rapamycin and histone deacetylase inhibitor may effectively prevent type 1 diabetes.
    Jiang GX; Cui YF; Zhong XY; Tai S; Liu W; Wang ZD; Shi YG
    Arch Med Res; 2009 Jul; 40(5):424-6. PubMed ID: 19766909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes.
    Boettler T; Pagni PP; Jaffe R; Cheng Y; Zerhouni P; von Herrath M
    J Autoimmun; 2013 Aug; 44():40-8. PubMed ID: 23770292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microbes as triggers and boosters of Type 1 Diabetes - Mediation by molecular mimicry.
    Repac J; Božić B; Božić Nedeljković B
    Diabetes Res Clin Pract; 2023 Aug; 202():110824. PubMed ID: 37429362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of low avidity T cells in the protection against type 1 diabetes: a modeling investigation.
    Khadra A; Santamaria P; Edelstein-Keshet L
    J Theor Biol; 2009 Jan; 256(1):126-41. PubMed ID: 18950644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential role of dendritic cells in the therapy of Type 1 diabetes.
    Lee CN; Lew AM; Wu L
    Immunotherapy; 2013 Jun; 5(6):591-606. PubMed ID: 23725283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.